13.89
price up icon0.22%   0.03
after-market 시간 외 거래: 13.95 0.06 +0.43%
loading
전일 마감가:
$13.86
열려 있는:
$13.99
하루 거래량:
87,577
Relative Volume:
0.97
시가총액:
$12.11B
수익:
$630.20M
순이익/손실:
$37.73M
주가수익비율:
69.45
EPS:
0.2
순현금흐름:
$-17.44M
1주 성능:
+3.66%
1개월 성능:
-8.38%
6개월 성능:
-18.05%
1년 성능:
-26.31%
1일 변동 폭
Value
$13.60
$14.02
1주일 범위
Value
$13.13
$14.02
52주 변동 폭
Value
$11.51
$21.50

Hutchmed China Limited Adr Stock (HCM) Company Profile

Name
명칭
Hutchmed China Limited Adr
Name
전화
-
Name
주소
-
Name
직원
1,811
Name
트위터
@hchimed
Name
다음 수익 날짜
2025-03-19
Name
최신 SEC 제출 서류
Name
HCM's Discussions on Twitter

HCM을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
HCM
Hutchmed China Limited Adr
13.89 2.29B 630.20M 37.73M -17.44M 0.20
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.35 50.14B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
168.63 72.38B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.79 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 45.51B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.78 19.45B 16.54B -1.64B 749.00M -1.45

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-13 다운그레이드 HSBC Securities Buy → Hold
2023-11-24 업그레이드 Deutsche Bank Hold → Buy
2022-05-04 다운그레이드 Deutsche Bank Buy → Hold
2021-09-22 다운그레이드 Goldman Buy → Neutral
2021-08-03 개시 Jefferies Buy
2020-10-02 개시 Deutsche Bank Buy
2020-03-13 개시 Cantor Fitzgerald Overweight
2020-02-20 개시 Goldman Buy
2019-11-19 개시 CLSA Buy
2019-10-23 재확인 BofA/Merrill Buy
2019-07-05 개시 Macquarie Outperform
모두보기

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 26, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 24, 2025
pulisher
May 20, 2025

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 20, 2025
pulisher
May 16, 2025

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 16, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

May 16, 2025
pulisher
May 15, 2025

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

May 15, 2025
pulisher
May 13, 2025

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times

May 13, 2025
pulisher
May 12, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.

May 12, 2025
pulisher
May 09, 2025

International companies to host live webcasts at Deutsche - GlobeNewswire

May 09, 2025
pulisher
May 06, 2025

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

May 05, 2025
pulisher
Apr 29, 2025

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

Apr 29, 2025
pulisher
Apr 23, 2025

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

Apr 21, 2025
pulisher
Mar 24, 2025

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

Mar 24, 2025
pulisher
Mar 23, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Mar 23, 2025
pulisher
Mar 20, 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

Mar 18, 2025
pulisher
Mar 09, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

Mar 09, 2025
pulisher
Feb 20, 2025

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

Feb 19, 2025
pulisher
Feb 17, 2025

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Feb 17, 2025
pulisher
Feb 04, 2025

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Feb 04, 2025
pulisher
Jan 28, 2025

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jan 28, 2025
pulisher
Jan 16, 2025

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

Jan 16, 2025
pulisher
Jan 13, 2025

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

Jan 13, 2025
pulisher
Jan 07, 2025

UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com

Jan 07, 2025
pulisher
Jan 05, 2025

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance

Jan 05, 2025
pulisher
Jan 05, 2025

HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com

Jan 05, 2025
pulisher
Jan 02, 2025

Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast

Jan 02, 2025
pulisher
Jan 02, 2025

Market news - Research the market

Jan 02, 2025
pulisher
Jan 02, 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive

Jan 02, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times

Jan 01, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire

Jan 01, 2025
pulisher
Dec 29, 2024

Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World

Dec 28, 2024
pulisher
Dec 12, 2024

HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times

Dec 12, 2024
pulisher
Dec 11, 2024

HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire

Dec 11, 2024
pulisher
Dec 03, 2024

Hutchmed endometrial cancer treatment gets conditional approval in China - ShareCast

Dec 03, 2024
pulisher
Nov 30, 2024

Why Alibaba Group Holding Limited (BABA) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance

Nov 30, 2024
pulisher
Nov 04, 2024

How Trump and Harris plan to address housing affordability - Yahoo Finance

Nov 04, 2024
pulisher
Oct 16, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial - Yahoo Finance

Oct 15, 2024

Hutchmed China Limited Adr (HCM) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$123.02
price down icon 0.52%
drug_manufacturers_specialty_generic RDY
$14.72
price down icon 0.20%
drug_manufacturers_specialty_generic RGC
$877.00
price up icon 18.36%
$318.85
price down icon 0.47%
$16.78
price down icon 4.28%
자본화:     |  볼륨(24시간):